DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Antitumoral activity of a CDK9 PROTAC compound in HER2-Positive breast cancer
Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9. Breast cancer cell lines from different subtypes were used. Transcriptomic mapping of CDKs in breast cancer demonstrated that the expression of CDK9 predicted a detrimental outcome in basal-like tumors (HR = 1.51, CI = 1.08–2.11, p = 0.015) and, particularly, in the luminal B subtype with HER2+ expression (HR = 1.82, CI = 1.17–2.82, p = 0.0069). The novel CDK9 PROTAC, THAL-SNS-032, displayed a profound inhibitory activity in MCF7, T47D, and BT474 cells, with less effect in SKBR3, HCC1569, HCC1954, MDA-MB-231, HS578T, and BT549 cells. The three cell lines with HER2 overexpression and no presence of ER, SKBR3, HCC1569, and HCC1954 displayed an EC50 three times higher compared to ER-positive and dual ER/HER2-positive cell lines. BT474-derived trastuzumab-resistant cell lines displayed a particular sensitivity to THAL-SNS-032. Western blot analyses showed that THAL-SNS-032 caused a decrease in CDK9 levels in BT474, BT474-RH, and BT474-TDM1R cells, and a significant increase in apoptosis. Experiments in animals demonstrated an inverse therapeutic index of THAL-SNS-032, with doses in the nontherapeutic and toxic range. The identified toxicity was mainly due to an on-target off-tumor effect of the compound in the gastrointestinal epithelium. In summary, the potent and efficient antitumoral properties of the CDK9 PROTAC THAL-SNS-032 opens the possibility of using this type of compound in breast cancer only if specifically delivered to cancer cells, particularly in ER/HER2-positive and HER2-resistant tumors., These results have been supported by Instituto de Salud Carlos III (PI19/00808), ACEPAIN, Diputación de Albacete, CIBERONC, and CRIS Cancer Foundation (to A.O.); Junta de Comunidades de Castilla-La Mancha (SBPLY/19/180501/000173) (to E.M.G.-M. and A.O.); the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R and PID2020-115605RB-I00), the Instituto de Salud Carlos III through the CIBERONC, Junta de Castilla y León (CSI146P20), the CRIS Foundation, ALMOM, ACMUMA, and UCCTA Non-profit Associations (to A.P.). The work carried out in our laboratories receives support from the European Community through the regional development funding program (FEDER). M.N.-L. was supported by the Spanish Ministry of Education (FPU grant; Ref.: FPU18/01319). L.G.-S. is a recipient of a predoctoral contract (BES-2016-077748). E.M.G.-M. holds a Investigador Distinguido contract from the UCLM. R.L.-R. and D.T.-G. are hired under the auspices of the abovementioned grant (SBPLY/19/180501/000173, IP: E.M.G.-M.). M.B. is funded by a Castilla-La Mancha support grant for Biomedicine and Health Science Research ref.: II-2018_11.